Detalle Publicación


The 18F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea).; Cualificacion de fantomas 18F para ensayos clinicos con imagen PET/TC-18F-FDG adoptada por GELTAMO (Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea).

Autores: Bergesio, F.; De Maggi, A.; Coronado, M.; Pardal, E.; Plaza, R.; Hernandez, A. C.; Sarandeses, M.; Cortes, M.; Setoain, X.; Simo, M.; Rotger, A.; Grande García, Carlos; Caballero, M.; Chauvie, S.
ISSN: 2253-8070
Volumen: 40
Número: 3
Páginas: 149-154
Fecha de publicación: 2021
INTRODUCTION AND OBJECTIVES: Since different PET/CT (Positron Emission Tomography/Computed Tomography) scanners give different qualitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of PET/CT in prospective multi-centre clinical trials. Within this work we will show the results carried out in performing CTQ in Spain. MATERIALS AND METHODS: We set up, under the auspices of Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea (GELTAMO), a CTQ program consisting of the acquisition and analysis of 18F uniformity and image quality phantoms for the reduction of inter-scanner variability (ISV). The ISV was estimated on background activity concentration (BAC) and sphere to background ratio (SBR) and defined as their 95% confidence level. RESULTS: Twenty-six out of 27 (96%) scanners fulfilled the CTQ requirements. The CTQ was fulfilled at the first round in 27% of the cases, while in 38%, 15% and 20%, two, three or more than three iterations, were required, respectively. The mean CTQ time was (1.8 ± 1.4) months (range: 0.3-4.6). The ISV in BAC and SBR were 20.3% and 67.7%. CONCLUSIONS: The CTQ proven to be a reliable tool to reduce ISV. This enabled to set-up clinical trials in which PET/CT was used to evaluate different clinical endpoints. Copyright © 2020 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier Espana, S.L.U. All rights reserved.